Moderna and MSD Achieve Breakthrough With Personalized mRNA Cancer Vaccine in Phase 3 Trial

Moderna and Merck (known as MSD in Israel) have announced promising results from a Phase 3 clinical trial of a personalized mRNA-based cancer treatment for high-risk melanoma patients post-surgery. Unlike conventional drugs where all patients receive the same treatment, this vaccine is custom-made for each patient based on the genetic profile of their tumor, targeting unique neoantigens to stimulate the immune system. The experimental vaccine, called intismeran autogene (also known as V940 or mRNA-4157), was administered alongside pembrolizumab (Keytruda), an established PD-1 immune checkpoint inhibitor, aiming to enhance immune response and prevent cancer recurrence.

The global, randomized, double-blind INTerpath-001 trial involved 1,089 melanoma patients with stage IIB to IV disease who had their tumors surgically removed. The combination treatment showed a statistically significant improvement in disease-free survival and reduced distant metastases compared to pembrolizumab alone, marking the first time a personalized mRNA cancer vaccine demonstrated positive Phase 3 results. However, full data including the exact risk reduction rates have yet to be published and will be presented at an upcoming medical conference and submitted for regulatory review.

Experts like Prof. Gal Markel from Beilinson Cancer Center called the findings a "breakthrough," emphasizing that this is the first Phase 3 study to show efficacy of a personalized immunotherapy based on individual tumor characteristics beyond the effect of pembrolizumab. MSD Israel CEO Dr. Eliad Ben-Dayan highlighted the significance of this milestone in melanoma treatment and the potential for expanding this approach to other cancers such as non-small cell lung cancer, bladder, and kidney cancers.

Melanoma remains a significant health issue in Israel, with an estimated 2,130 new cases expected by 2026 and 229 deaths recorded in 2022. While the path to routine clinical use requires further safety and efficacy evaluation and regulatory approvals, this success signals a major advance in personalized cancer immunotherapy, potentially transforming treatment paradigms by tailoring vaccines to the molecular profile of each patient’s tumor.